Drug Trial Radar · NCT00704353
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
735
Actual
Start
Jun 2008
Primary completion
Jul 2009
Study completion Mar 2011
Sponsor
- Lead sponsor
- American Regent, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent
Conditions
- Anemia
Interventions
Ferric CarboxymaltoseDrug
15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
Standard Medical Care (SMC)Drug
Per product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)Time frame: through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Luitpold Pharmaceuticals
Norristown, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.